Lumos Pharma Profit Margin 2009-2021 | LUMO

Current and historical gross margin, operating margin and net profit margin for Lumos Pharma (LUMO) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Lumos Pharma net profit margin as of June 30, 2021 is 0%.
Lumos Pharma Annual Profit Margins
Lumos Pharma Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.079B $0.000B
Lumos Pharma Inc. is a clinical stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics for rare and neglected diseases. The company's product pipeline consists of LUM-201 which is in clinical stage. Lumos Pharma Inc., formerly known as NewLink Genetics Corporation, is based in AUSTIN, Texas.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.972B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $11.985B 20.30
Biohaven Pharmaceutical Holding (BHVN) United States $8.378B 0.00
Emergent Biosolutions (EBS) United States $2.740B 6.61
Arcus Biosciences (RCUS) United States $2.509B 0.00
Myovant Sciences (MYOV) United Kingdom $1.869B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.763B 0.00
Zymeworks (ZYME) Canada $1.061B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.333B 0.00
Enzo Biochem (ENZ) United States $0.157B 15.43